Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 5/20 | 0.48 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31122321 | 0.85 | HSP90AA1 (0.42) | CXCR2CXCR1HSP90AA1HSP90AB1ATR | |
| SCHEMBL19932183 | 0.82 | TAS1R3 (0.42) | HSP90AA1HSP90AB1ATRLCKMEN1 | |
| SCHEMBL28146075 | 0.79 | MEN1 (0.60) | LCKMEN1MAPK1KMT2ALMNA | |
| SCHEMBL5562914 | 0.79 | PRMT1 (0.41) | HSP90AA1HSP90AB1ATRLCKMEN1 | |
| SCHEMBL34472852 | 0.78 | ATR (0.41) | HSP90AA1HSP90AB1ATRLCKCYP17A1 | |
| SCHEMBL5423774 | 0.78 | PDK1 (0.57) | HSP90AA1HSP90AB1ATRLCKCYP17A1 | |
| SCHEMBL29534865 | 0.78 | ATR (0.41) | HSP90AA1HSP90AB1ATRLCKMEN1 | |
| SCHEMBL3784448 | 0.77 | GPR35 (0.50) | HSP90AA1HSP90AB1ATRLCKMEN1 | |
| SCHEMBL28738831 | 0.76 | PDK1 (0.56) | HSP90AA1HSP90AB1MEN1KMT2APOLB | |
| SCHEMBL6056066 | 0.76 | RAB9A (0.54) | MEN1KMT2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2022266458-A1 | 6-HETEROCYCLOALKYL-QUINAZOLINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| WO-2018045246-A1 | CXCR3 RECEPTOR AGONISTS | CELGENE INTERNATIONAL II SARL (CH) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | CXCR2 4/4885CXCR1 2/4885HSP90AA1 2961/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | CXCR2 4/4885CXCR1 2/4885HSP90AA1 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.